10x Genomics (TXG) Stock Price, News & Analysis

Company Overview

10x Genomics, Inc. develops life science technology for analyzing biological systems at the single-cell and spatial levels. Its platforms are designed to help researchers study gene expression, genetic variation, cell populations and tissue organization with greater detail than conventional laboratory methods.

The company’s product portfolio includes the Chromium platform for single-cell analysis, Visium solutions for spatial transcriptomics and tissue profiling, and Xenium in situ platforms for high-resolution analysis of RNA and other biological features within tissue samples. These products generally combine specialized instruments, consumables, reagents and software for use in applications such as oncology, immunology, neuroscience, developmental biology and drug discovery.

Founded in 2012 and headquartered in Pleasanton, California, 10x Genomics serves academic, government, pharmaceutical and biotechnology research organizations worldwide. The company was co-founded by Serge Saxonov, who serves as its chief executive officer, and its technologies are used by researchers seeking to understand complex biological processes and develop new approaches to disease research and precision medicine.

Key Stats

• Today's Range: $76.73 to $80.11
• 50-Day Range: $41.77 to $76.97
• 52-Week Range: $11.16 to $80.11
• Volume: 2.43 million shs
• Average Volume: 2.86 million shs
• Market Capitalization: $10.31 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $44.00
• Consensus Rating: Hold

10x Genomics Stock Analysis - MarketRank™

10x Genomics scored higher than 31% of companies evaluated by MarketBeat, and ranked 742nd out of 895 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.1 / 5
• Analyst Rating: Hold

Consensus Rating

10x Genomics has received a consensus rating of Hold. The company's average rating score is 2.24, and is based on no strong buy ratings, 5 buy ratings, 11 hold ratings, and 1 sell rating.

Downside Risk

10x Genomics has a consensus price target of $44.00, representing about 44.4% downside from its current price of $79.10.

Amount of Analyst Coverage

10x Genomics has been the subject of 11 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for 10x Genomics are expected to grow in the coming year, from ($0.75) to ($0.67) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of 10x Genomics is -134.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of 10x Genomics is -134.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

10x Genomics has a P/B Ratio of 12.68. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

13.61% of the float of 10x Genomics has been sold short.

Short Interest Ratio / Days to Cover

10x Genomics has a short interest ratio ("days to cover") of 5.51.

Change versus previous month

Short interest in 10x Genomics has recently increased by 1.47%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

10x Genomics does not currently pay a dividend.

Dividend Growth

10x Genomics does not have a long track record of dividend growth.

News and Social Media

• Score: 3.6 / 5
• News Sentiment: 0.80

News Sentiment

10x Genomics has a news sentiment score of 0.80. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.54 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 12 news articles for 10x Genomics this week, compared to 6 articles on an average week.

Search Interest

Only 4 people have searched for TXG on MarketBeat in the last 30 days. This is a decrease of -69% compared to the previous 30 days.

MarketBeat Follows

7 people have added 10x Genomics to their MarketBeat watchlist in the last 30 days. This is an increase of 40% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, 10x Genomics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $10,348,120.00 in company stock.

Percentage Held by Insiders

8.84% of the stock of 10x Genomics is held by insiders.

Percentage Held by Institutions

84.68% of the stock of 10x Genomics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/06/2026
• Today: 9/21/2026
• Next Earnings (Estimated): 11/05/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Life Sciences Tools & Services
• Sub-Industry: Life Sciences Tools & Services
• Current Symbol: NASDAQ:TXG
• CIK: 1770787
• Web: www.10xgenomics.com
• Phone: 925-401-7300
• Fax: N/A
• Employees: 1,178
• Year Founded: 2012

Price Target and Rating

• Average Price Target for 10x Genomics: $44.00
• High Price Target: $70.00
• Low Price Target: $17.00
• Potential Upside/Downside: -44.4%
• Consensus Rating: Hold
• Rating Score (0-4): 2.24
• Research Coverage: 17 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.59)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$43.54 million
• Net Margins: -12.18%
• Pretax Margin: -12.14%
• Return on Equity: -9.33%
• Return on Assets: -7.30%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 5.69
• Quick Ratio: 5.25

Sales & Book Value

• Annual Sales: $616.91 million
• Price / Sales: 16.71
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $6.24 per share
• Price / Book: 12.68

Miscellaneous

• Outstanding Shares: 130,291,000
• Free Float: 118,773,000
• Market Cap: $10.31 billion
• Optionable: Optionable
• Beta: 2.08